AccutarBio

AccutarBio is a startup founded in 2020 based in the United States. Its most recent tracked round is Series C+. Brouky classifies it under Software & Developer Tools. Brouky records 2 investors associated with the company.

AccutarBio is a clinical-stage biotech company leveraging artificial intelligence to accelerate drug discovery. It uses a hybrid approach of computational drug design followed by wet-lab validation to reduce time and costs in traditional drug discovery efforts, focusing on targeted protein degradation therapies.